New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2012
10:08 EDTIMMUImmunomedics provides update on subcutaneous injections of Veltuzumab
Immunomedics announced that subcutaneous administration of veltuzumab, as a single agent, demonstrated promising activity in patients with relapsed immune thrombocytopenia, even in more heavily treated patients with the chronic disease, and in patients with chronic lymphocytic leukemia. In a published study, veltuzumab reversed life threatening anemia and thrombocytopenia in a patient with systemic lupus erythematosus who was unresponsive to rituximab. In non-Hodgkin lymphoma patients who had received prior therapies, 4 once-weekly infusions of veltuzumab produced a complete response rate of 25% in a study of 84 patients, even at the low dose of 80 mg/m2 given intravenously.
News For IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 19, 2015
14:34 EDTIMMUImmunomedics presents updated results with sacituzumab govitecan in lung cancer
Immunomedics announced that 33% of patients with small cell lung cancer, SCLC, and 31% with non-small cell lung cancer, NSCLC, had their tumor reduced in size by 30% or more, after being treated with sacituzumab govitecan, the company's lead investigational antibody-drug conjugate, ADC. Including patients that reported stable disease as their best response, the ADC controls the progression of the cancer in 75% and 56% of NSCLC and SCLC patients, respectively. These patients had either failed to respond to their last lung cancer therapies or their cancer had returned or progressed. Dr. Francois Wilhelm, Chief Medical Officer, presented the updated results at the 15th Annual Targeted Therapies of Lung Cancer Meeting, an invitation-only meeting sponsored by The International Association for the Study of Lung Cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use